Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Chembiochem. 2021 May 28;22(13):2335–2344. doi: 10.1002/cbic.202100118

Figure 6: Overview of CBX2 inhibitor function during prostate cancer NED.

Figure 6:

A) Androgen deprivation initiates the gradual repression of AR target genes by EZH2 and CBX2, resulting in the emergence of a neuroendocrine phenotype that is resistant to anti-androgen therapy. B) Inhibition of CBX2 during androgen deprivation prevents neuroendocrine differentiation and maintains prostate cancer cell susceptibility to anti-androgen therapy.